The recent publication in JAMA Network Open on September 18 presented a sweeping look at how the two newly authorized RSV vaccines perform in real-world settings. Researchers from the U.S. Food and Drug Administration examined health records of 14.8 million Medicare beneficiaries aged 65 and older, tracking hospital admissions and mortality linked to respiratory syncytial virus. The analysis showed an approximately 80% reduction in both hospitalizations and death among those who had received either the GlaxoSmithKline or Pfizer product.
Dr. Edward Walsh, a professor of medicine at the University of Rochester, noted that early phase trials were conducted during a lull in RSV circulation, which left some scientists uneasy about how the vaccines would hold up when the virus returned in full force. The new data, however, “paralleled and mimicked the exact results of the efficacy trials,” providing strong reassurance that the earlier expectations were not a statistical artifact.
Real-world effectiveness across the entire senior population
The FDA’s cohort encompassed the full spectrum of Medicare-eligible adults, making it considerably larger than the handful of prior investigations that focused on limited geographic areas or specialty groups. Within this massive sample, vaccine recipients were more likely to live in higher-income zip codes and to have already accepted seasonal flu or COVID-19 shots, raising concerns that better access to health care might be inflating the observed benefits. A dedicated statistical adjustment for health-care access, however, left the 80% efficacy figure essentially unchanged, confirming that the protective effect is genuine and not merely a proxy for socioeconomic advantage.
Both the GSK-produced AREXVY and Pfizer’s ABRYSVO performed on par with each other, and the newer Moderna mRNA candidate, authorized in 2024, saw slower uptake—likely because many seniors had already completed the initial series when it arrived.
Who is recommended to receive an RSV vaccine and how it fits into routine care
The current immunization landscape includes three licensed products for adults 50 years and older: GSK’s AREXVY, Pfizer’s ABRYSVO, and Moderna’s mRESVIA. Health agencies do not express a preference for any single brand; each is administered as a single dose and is not required annually. The ideal timing is in late summer or early fall, just before the traditional RSV season, and the shot can be given alongside flu, COVID-19, or other vaccines during the same visit.
Eligibility extends beyond age alone. Adults with chronic heart or lung disease, renal failure, neuromuscular disorders, immune suppression, obesity (BMI ≥ 40), or those residing in long-term-care facilities are flagged as high-risk and strongly encouraged to be vaccinated. Pregnant individuals may receive Pfizer’s ABRYSVO between 32 and 36 weeks gestation to confer passive protection to newborns during their first RSV season.
For infants and young children, protection primarily comes from long-acting monoclonal antibodies such as nirsevimab (BEYFORTUS™) or clesrovimab (ENFLONSIA™), which serve a similar purpose to vaccines by providing ready-made antibodies. In California, these antibodies are typically administered from October through March, with timing adjusted according to the infant’s birth month.
Open questions: boosters, durability, and broader respiratory protection
While the current data are reassuring, the next chapter involves understanding whether additional doses are needed to sustain immunity. Dr. Walsh points out that a second administration of an RSV vaccine does not elicit the same “vigorous antibody response” observed after the first dose, a pattern differing from the annual flu shot, where antigenic drift drives the need for yearly revaccination. Ongoing trials aim to determine if a booster given two or three years after the initial series can meaningfully refresh protection, or if the waning immunity observed after the first dose is sufficient to forego further injections.
Beyond RSV, immunologists are exploring the concept of a universal respiratory vaccine—one that could stimulate the innate immune system in a non-specific manner to fend off multiple viral foes such as parainfluenza, influenza, and even emerging coronaviruses. The observation that infection with one respiratory virus sometimes shields against another fuels this line of inquiry, although a commercially viable product remains years away.
In the meantime, the concrete takeaway for seniors, caregivers, and clinicians is clear: the approved RSV vaccines dramatically lower the risk of severe disease, mirroring the success seen in controlled trials. By integrating the shot into existing vaccination schedules and targeting those with underlying health conditions, public health officials hope to curb the winter surge of RSV-related morbidity and mortality that has long plagued older adults.
